Three Not A Magic Number For Mayne With Another NuvaRing CRL
Follows CRLs Handed Out By US FDA To Australian Firm In 2018 And 2020
Australia’s Mayne Pharma has announced another complete response letter for its proposed generic version of Organon’s NuvaRing (etonogestrel/ethinylestradiol) contraceptive device, marking a trio of setbacks for the ANDA product.
